Navigation Links
Cadence Pharmaceuticals to Raise up to $49.3 Million in Registered Direct Common Stock Offering
Date:2/15/2008

SAN DIEGO, Feb. 15 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX) a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that Cadence has received commitments from selected investors to purchase up to 9,240,307 shares of Cadence's common stock at a purchase price of $5.34 per share pursuant to an effective shelf registration statement.

The closing of the offering is expected to take place on February 20, 2008. The total number of shares to be sold in the offering may be reduced to 8,056,716 and the gross proceeds may be reduced to $43.0 million pursuant to Nasdaq Marketplace Rule 4350(i)(1)(B) limitations, pending the determination of the applicability of such rule prior to the closing of the offering.

Copies of the final prospectus supplement and accompanying base prospectus relating to this offering may be obtained from Cadence Pharmaceuticals, Inc., 12481 High Bluff Drive, Suite 200, San Diego, California, Attention: General Counsel, or by calling (858) 436-1400.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

About Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company currently has two Phase III product candidates in development, Acetava
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
2. Cadence Pharmaceuticals Names Malvina Laudicina Vice President of Regulatory Affairs and Quality Assurance
3. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at UBS 2007 Global Life Sciences Conference
4. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BIO Investor Forum
5. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BIOCOM Investor Conference 2007
6. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2007 Financial Results
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on February 5, 2008 in New York
8. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
9. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... researchers at the USC Viterbi School of Engineering, ... microfluidic system quickly and cheaply by simply snapping ... systems are used in many fields including engineering, ... of fluids for use in applications such as ... testing, and synthetic chemistry. Traditionally, microfluidic devices are ...
(Date:9/22/2014)... in a mouse model of pancreatic cancer identified distinct ... including significant differences from the primary tumor that may ... their study reported in the Sept. 25 issue of ... Hospital (MGH) Cancer Center identified several different classes of ... to be targets for improved treatment of the deadly ...
(Date:9/22/2014)... researchers have developed a unique nanoscale device that ... light. The discovery could have major implications for ... computation and communication. , The research paper by ... professor Mo Li and his graduate student Huan ... in the October issue of Nature Nanotechnology ...
(Date:9/22/2014)... September 22, 2014 Lawrence Livermore ... John DeGioia on Friday renewed their institutional commitment ... additional five years to expand the collaborative work ... and global climate, energy and environmental sciences. , ... MOU originally signed in December 2009 and is ...
Breaking Biology Technology:Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 2Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 3Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 4Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 5Massachusetts General study reveals gene expression patterns in pancreatic CTCs 2Massachusetts General study reveals gene expression patterns in pancreatic CTCs 3Engineers show light can play seesaw at the nanoscale 2Lawrence Livermore Renews Pact with Georgetown University to Expand Research and Education in Science and Policy 2
... - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY ... investment in British Canadian Biosciences Corp. (BCBC), a privately ... for the treatment of a variety of conditions, including ... preferred shares of BCBC in exchange for 200,000 common ...
... The Case Western Reserve University Biomedical Engineering Department ... benefiting newborns and the aged, the critically ill and ... the future as it celebrates its 40th anniversary, Thursday, ... first universities in the nation to offer graduate and ...
... HARRISBURG, Pa., Oct. 20 PresentCare, a technology ... AdherencePlus(TM) solution, an innovative approach to assist the ... medication non-adherence. The AdherencePlus solution is comprised ... communication technology combined with unprecedented human touch. Both ...
Cached Biology Technology:Oncolytics Biotech(R) Inc. Announces Investment in Private Biotechnology Company 240 Years on the Leading Edge: Case Western Reserve University's Biomedical Engineering Department Commemorates Achievement, Looks to Future 2Medication Adherence Technology Combines with Patient Outreach Program to Yield Healthier Populations and Reduce Healthcare Costs 2Medication Adherence Technology Combines with Patient Outreach Program to Yield Healthier Populations and Reduce Healthcare Costs 3
(Date:9/22/2014)... A new American Cancer Society study suggests that ... previously known as the food stamp program, had ... non-participants. The authors say the findings emphasize the ... dietary quality of SNAP participants. , The SNAP ... with the resources to obtain a nutritionally adequate ...
(Date:9/22/2014)... researchers are studying a potential new treatment that reverses ... which scars develop in the lungs and severely hamper ... which is delivered to lung tissue intravenously. In mouse ... fibrosis after several days. , The findings were ... Medicine . , "The mimic, when injected into the ...
(Date:9/22/2014)... As genetic sequencing technologies continue to evolve rapidly, becoming ... to establish appropriate policies and regulatory frameworks to address ... special policy issue of the Journal of Law, ... by experts with the Center for Medical Ethics and ... makers the tools to jumpstart this process. , ...
Breaking Biology News(10 mins):Federal food program puts food on the table, but dietary quality could be improved 2Reversing the effects of pulmonary fibrosis 2Experts provide much-needed policy analysis for clinical integration of next generation sequencing 2Experts provide much-needed policy analysis for clinical integration of next generation sequencing 3
... by suppressing one of the genes that normally switches on ... This has major implications not just for wound victims but ... or abdominal surgery. When skin is damaged a blood ... the damage, leading to scarring. Scarring is a natural part ...
... French and German . ... EPFL in Switzerland have developed a novel method for ... medical and industrial imaging equipment. Dark-field images provide ... used to diagnose the onset of osteoporosis, breast cancer ...
... is available in French . , A ... small differences between individuals at the DNA level can ... proteins. These, in turn, are responsible for the vast ... study, part of the Genome Regulators in Disease (GRID) ...
Cached Biology News:Skin care: new research into scar-free healing 2New technology sharpens X-ray vision 2Tiny genetic differences have huge consequences: McGill researchers 2
...
Denhardt's powder mixture (for 50X stock solution)...
... SYBR Green Mixes are optimised for SYBR Green ... to perform Quantitative PCR, with the exception of ... Mix contains optimal levels of active SYBR Green ... a proprietary reaction buffer that enables detection of ...
... Roto-Shake Genie is an all-in-one rotator/rocker ... performs five different mixing motions: ... as well as a combination of ... moving portion of the Vibraotme Roto-Shake ...
Biology Products: